NASDAQ:AVEO

AVEO Pharmaceuticals (AVEO) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$14.99
$15.00
50-Day Range
$14.90
$15.00
52-Week Range
$3.06
$15.00
Volume
247,800 shs
Average Volume
601,442 shs
Market Capitalization
$521.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AVEO stock logo

About AVEO Pharmaceuticals Stock (NASDAQ:AVEO)

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

AVEO Stock News Headlines

The system that called 2023’s top 7 stocks is at it again…
Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.
The system that called 2023’s top 7 stocks is at it again…
Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.
Actinium Appoints Lynn Bodarky as Chief Business Officer
C-MET / HGF Inhibitors Market Forecast to 2030
C-MET & HGF Inhibitors Market Growth by 2030
See More Headlines
Receive AVEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AVEO
CUSIP
05358810
Employees
114
Year Founded
2001

Profitability

Net Income
$-53,340,000.00
Pretax Margin
-30.79%

Debt

Sales & Book Value

Annual Sales
$42.29 million
Book Value
$1.33 per share

Miscellaneous

Free Float
33,619,000
Market Cap
$521.45 million
Optionable
Optionable
Beta
1.00

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives


AVEO Stock Analysis - Frequently Asked Questions

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) issued its quarterly earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.36) by $0.06. The biopharmaceutical company had revenue of $15.17 million for the quarter, compared to analyst estimates of $14.29 million. AVEO Pharmaceuticals had a negative net margin of 30.79% and a negative trailing twelve-month return on equity of 81.66%. During the same quarter in the prior year, the firm earned ($0.33) EPS.

When did AVEO Pharmaceuticals' stock split?

Shares of AVEO Pharmaceuticals reverse split before market open on Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 19th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Tuan Ha-Ngoc's approval rating as AVEO Pharmaceuticals' CEO?

4 employees have rated AVEO Pharmaceuticals Chief Executive Officer Tuan Ha-Ngoc on Glassdoor.com. Tuan Ha-Ngoc has an approval rating of 61% among the company's employees. This puts Tuan Ha-Ngoc in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at AVEO Pharmaceuticals to a friend.

What other stocks do shareholders of AVEO Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA).

This page (NASDAQ:AVEO) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners